DiaTech Holdings, Inc.
405 Duke Drive
Suite 240
Franklin
Tennessee
37067
United States
Tel: 615-567-0200
Fax: 615-567-0201
Website: http://www.diatech-oncology.com/
Email: info@diatech-oncology.com
About DiaTech Holdings, Inc.
DiaTech Holdings is an emerging oncology focused biotechnology company specializing in cutting edge technologies utilizing molecular based clinical assays to generate actionable data for improved patient outcomes. We are currently focused on the MiCK (Micro Culture Kinetic assay), CEER (Collaborative Enzyme Enhanced Reactive-immunoassay), and flow cytometer technology platforms in support of our In Vitro Diagnostic (IVD) product development, FDA clinical validation studies and biophama collaborative projects.7 articles about DiaTech Holdings, Inc.
-
DiaTech Oncology Receives New York State Clinical Laboratory Permit
6/25/2013
-
DiaTech Oncology Test Shows Positive Results, Identifies New Therapeutic Strategies for Patients With Lung Cancer and Ovarian Cancer
6/19/2013
-
DiaTech Oncology Announces Capital Raise of $18 Million
6/4/2013
-
DiaTech Oncology Test Predicts Most Effective Chemotherapy for Cancer Patients
1/15/2013
-
DiaTech Oncology Test Shows Improved Results for Breast Cancer Patients
12/10/2012
-
DiaTech Oncology and Walter Reed Army Institute of Research Establish Pilot to Determine Best Chemotherapy for Cancer Patients
2/8/2011
-
DiaTech Oncology MiCK Chemotherapy Induced Apoptosis Assay Shows Increased Response and Survival in Ovarian Cancer Patients
5/26/2010